Overview

Adaptive Modification of Neoadjuvant Therapy Based on Clinical Response in Patients With Localized Pancreatic Cancer

Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
This is an open-label, phase II study in patients with resectable and borderline resectable pancreas cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Medical College of Wisconsin
Treatments:
Fluorouracil